Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Unemployment Looms As A Threat To Pharma, But More Impact In 2021

Executive Summary

Sweeping job losses in the US have left people uninsured or transitioning from private insurance to Medicaid, which will impact how drugs are reimbursed. Changing payer mix will have an effect on company revenues.

You may also be interested in...



Lilly Points To Six-Month Growth Instead Of Pandemic Impacted Q2

Lilly argues the overall trend is positive, although the second quarter was down. Trial successes with Verzenio, Trulicity, Jardiance and mirikizumab offer additional growth potential.

Lilly May Face Q2 Blues As Prior Stocking Takes Effect

Changing payer mix in diabetes due to the impacts of COVID-19 may be a central focus of Lilly's second quarter earnings call.

10 Non-COVID News Updates To Listen For In Second Quarter Reporting

The pandemic is expected to dominate the industry's second quarter earnings calls, which kick off on 16 July, but here are 10 other topics to listen for.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC142191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel